Zymeworks and Hoffmann-La Roche Partner on ZW209 Development
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Zymeworks and Hoffmann-La Roche entered a global license and collaboration agreement for ZW209, a T cell engager targeting DLL3. Under the deal, Zymeworks will receive an upfront payment of $55 million and $40 million upon starting the Phase 1b trial. The agreement also includes potential milestones totaling up to $718 million and tiered royalties on global net sales. The transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
From saultstar.com
Why it matters
The collaboration involves Hoffmann-La Roche funding and developing ZW209, while Zymeworks receives substantial payments and royalties. This structure provides Zymeworks with significant financial upside tied to the drug's commercial success and regulatory milestones.
From saultstar.com
Who's involved
- ZymeworksBiotechnology company receiving payments and conducting the Phase 1a clinical trial of ZW209
- Hoffmann-La RocheSwiss healthcare company partnering to research, develop, and commercialize ZW209
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ZymeworksSpeculative
Zymeworks might see increased revenue from the upfront payments and royalties tied to ZW209's global net sales.
Keep exploring
The entities involved
-
Zymeworks
company
-
Hoffmann-La Roche
Swiss healthcare company